Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00972933 · ClinicalTrials.gov registry record · Early Phase 1
Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma
A Early Phase 1 study, sponsored by Diwakar Davar.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 59
- Enrollment target
NCT00972933 is a Early Phase 1 study that has completed, run by Diwakar Davar. The registered enrollment target is 59 participants.
The verdict
NCT00972933, a Early Phase 1 study, has completed, sponsored by Diwakar Davar.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 59 participants
- Enrollment target
Study Summary
Ipilimumab is a manufactured monoclonal antibody, much like the antibodies usually made by the human body to fight off infection; however it is not known why the human body does not "fight off" a cancerous tumor. The idea behind developing this experimental drug is to stimulate the immune system to make antibodies to kill cancer cells. This research study is considered "experimental" because it has not received approval from the Food and Drug Administration (FDA) for the treatment of this type of cancer. This monoclonal antibody has been specifically made to block Cytotoxic T Lymphocyte Antigen 4 (CTLA4), which is a protein found on cells of the immune system. CTLA4 seems to slow down the immune response, so blocking it with an anti-CTLA4 antibody may make the immune response more active. The purpose of this study is to see if Ipilimumab affects the response of the patient's immune system toward their cancer.
Interventions
- DRUG ipilimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2009-12 |
| Est. Completion | 2017-09-26 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00972933
The ClinicalTrials.gov registry entry for NCT00972933 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Diwakar Davar, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ipilimumab is the first listed.
NCT00972933 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00972933 about?
NCT00972933 is a clinical study titled "Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma". Ipilimumab is a manufactured monoclonal antibody, much like the antibodies usually made by the human body to fight off infection; however it is not known why the human body does not "fight off" a cancerous tumor. The idea behind developing this experimental drug is to stimulate the immune system to ...
What is the current status of trial NCT00972933?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 59 participants. The study started on 2009-12. Estimated completion is 2017-09-26.
What interventions are being tested in trial NCT00972933?
The interventions under investigation include: ipilimumab (DRUG).
Who is sponsoring clinical trial NCT00972933?
This trial is sponsored by Diwakar Davar, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.